Effects of natalizumab treatment on Foxp3+ T regulatory cells

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Stenner, Max Philipp ^a   Waschbisch, Anne ^a,b   Buck, Dorothea ^a,c   Doerck, Sebastian ^a   Einsele, Hermann ^a   Toyka, Klaus V ^a   Wiendl, Heinz ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; BETA INTERFERON; CD4 ANTIGEN; GLATIRAMER; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; NATALIZUMAB; TRANSCRIPTION FACTOR FOXP3; VERY LATE ACTIVATION ANTIGEN 4; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; MESSENGER RNA; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG MECHANISM; DRUG RESPONSE; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; MULTIPLE SCLEROSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; CASE CONTROL STUDY; CELL CULTURE; COHORT ANALYSIS; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM;

ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; CELLS, CULTURED; COHORT STUDIES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTEGRIN ALPHA4; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY;

EID: 53749105749     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003319     Document Type: Article

References (39)

1. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15-23.
2. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
3. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911-923.
4. Ransohoff RM (2007) Natalizumab for multiple sclerosis. N Engl J Med 356: 2622-2629.
5. Engelhardt B, Kappos L (2008) Natalizumab: Targeting alpha(4)-Integrins in Multiple Sclerosis. Neurodegener Dis 5: 16-22.
6. Kappos L, Bates D, Hartung HP, Havrdova F, Miller D, et al. (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6: 431-441.
7. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353: 375-381.
8. Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-la for multiple sclerosis. N Engl J Med 353: 369-374.
9. Stuve O, Bennett JL (2007) Pharmacological properties, toxicology and scientific rationale for the use of natafizumab (Tysabri) in inflammatory diseases. CNS Drug Rev 13: 79-95.
10. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687.
11. Mittelbrunn M, Molina A, Escribese MM, Yanez-Mo M, Escudero E, et al. (2004) VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc Natl Acad Sci U S A 101: 11058-11063.
12. Sato T, Tachibana, K, Nojima Y, D'Avirro N, Morimoto C (1995) Role of the VIA-4 molecule in T cell costimulation. Identification of the tyrosine hosphorylation pattern induced by the ligation of VLA-4. J Immunol 155: 2938-2947.
13. Niino M, Bodher C, Simard ML, Alatab S, Gano D, et al. (2006) Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 59: 748-754.
14. Stuve O, Marra CM, Bar-Or A, Niino M, Cravens PD, et al. (2006) Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63: 1383-1387.
15. Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, et al. (2006) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59: 743-747.
16. Baecher-Allan C, Hafler DA (2004) Suppressor T cells in human diseases. J Exp Med 200: 273-276.
17. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352.
18. Seale AC, de Jong BC, Zaidi I, Duvall M, Whittle H, et al. (2008) Effects of cryopreservation on CD4+ CD25+ T cells of HIV-1 infected individuals. J Clin Lab Anal 22: 153-158.
19. Schwab N, Waschbisch A, Wrobel B, Lochmiller H, Sommer C, et al. (2008) Human myoblasts modulate the function of antigen-presenting cells. J Neuroinummol.
20. Prat A, Al-Asmi A, Duquette P, Antell JP (1999) Lymphocyte migration and multiple sclerosis: relation with disease course and therapy. Ann Neurol 46 253-256.
21. Uhm JH, Dooley NP, Stuve O, Francis GS, Duquette P, et al. (1999) Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy. Ann Neurol 46: 319-324.
22. Stuve O, Dooley NP, Uhm JH, Antel JP, Francis GS, et al. (1996) Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40: 853-863.
23. Feger U, Luther C, Poeschel S, Melms A, Tolosa E, et al. (2007) Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 147: 412-418.
24. Feger U, Tolosa E, Huang YH, Waschbisch A, Biedermann T, et al. (2007) HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood 110: 568-577.
25. Theien BE, Vanderlugt CL, Eagar TN, Nickerson-Nutter C, Nazareno R, et al. (2001) Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 107: 995-1006.
26. Haas J, Hug A, Viehover A, Fritzsching B, Falk CS, et al. (2005) Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 35: 3343-3352.
27. Viglietta V, Baecher-Allan C, Weiner HL, Haller DA (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199: 971-979.
28. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, et al. (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203: 1701-1711.
29. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, et al. (2006) Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203: 1693-1700.
30. Valencia X, Lipsky PE (2007) CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol 3: 619-626.
31. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, et al. (2007) Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 13: 423-431.
32. Venken K, Hellings N, Hensen K, Rummens JL, Medaer R, et al. (2006) Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 83: 1432-1446.
33. McFarland HF, Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8: 913-919.
34. Hong J, Li N, Zhang X, Zheng B, Zhang JZ (2005) Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A 102: 6449-6454.
35. de Andres C, Aristimuno C, de Las Heras V, Martinez-Gines MI, Bartolome M, et al. (2007) Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J Neuroimmunol 182: 204-211.
36. Kleinschnitz C, Meuth SG, Kieseier BC, Wiendl H (2007) Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006. Endocr Metab Immune Disord Drug Targets 7: 35-63.
37. Bluestone JA, Thomson AW, Shevach EM, Weiner HL (2007) What does the future bold for cell-based tolerogenic therapy? Nat Rev Immunol 7: 650-654.
38. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, et al. (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110: 1225-1232.
39. Haas J, Fritzsching B, Trubswetter P, Korporal M, Milkova L, et al. (2007) Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol 179: 1322-1330.